Corporate
Affichem is a medical biotechnology company whose mission is to design, develop and market innovative therapeutic molecules and theranostic markers for the treatment of cancer and neurodegenerative diseases.
Created eight years ago, this Young Innovative Company is based in Toulouse, the second largest cancer research cluster in France.
Founded on the results of many years of academic research, this INSERM spin-off develops and enhances several families of molecules with high potential.
The first 2 families of proprietary molecules (AF122 and AF243) selected by Affichem are aimed at markets that have major and unsatisfied needs: metastatic melanoma (skin cancer), breast cancer, acute myeloid leukemia and deafness.
Affichem is also on the point of breaking into the diagnostics market with the discovery of a cancer biomarker for the detection and monitoring of the therapeutic efficacy of anti-cancer drugs.
This marker, intended for commercialization, but also for the optimization of internal clinical research, launches Affichem into the field of theranostics.